Comparative Pharmacology
Head-to-head clinical analysis: PENECORT versus XIPERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENECORT versus XIPERE.
PENECORT vs XIPERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
Triamcinolone acetonide is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and stabilizing lysosomal membranes. It also decreases vascular permeability and inhibits cytokine release.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
The recommended dose is 0.1 mL (containing 0.16 mg triamcinolone acetonide injectable suspension) administered by suprachoroidal injection to the affected eye(s) once every 3 months (every 12 weeks).
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
The terminal elimination half-life of triamcinolone acetonide following suprachoroidal administration is approximately 18 hours. This short half-life allows for sustained local effect with minimal systemic accumulation.
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
XIPERE (triamcinolone acetonide injectable suspension) is primarily eliminated via hepatic metabolism and subsequent renal excretion of metabolites. Approximately 40% of the dose is excreted renally as metabolites, with less than 5% as unchanged drug. Biliary/fecal excretion accounts for about 60% of the dose, mainly as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid